Want to join the conversation?
Simeon Siegel of Nomura asks about one-time costs. $SIG said the one-time costs that impacted 2Q17 amounted to about $5MM which was close to about $0.05 per share impact. There will be some additional costs related to this in 3Q17 and so there is about $3MM factored into the 3Q17 guidance associated with the same.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?